Introduction
Gastrin was first postulated by Edkins in 1906 as the hormone responsible for gastric acid secretion but it took a further 65 years of debate before Gregory and Tracey (1961) reported on the properties and structure of this hormone. With the elucidation of the complete amino acid structure and synthesis of the peptide, immunochemical and immunocytochemical methods quickly led to measurement of the hormone in blood and other biological fluids, localization, physiology and pathophysiology. Although gastrointestinal hormones were not amongst Avery Jones' primary interests in gastroenterology, the unit's expertise in peptic ulcer particularly with reference to bleeding led to the author's search for a possible role of gastrin in the pathophysiology of ulcer and to general studies of gastrin by radioimmuno assay.
This review will describe the advances in the past 20 years in gastrin physiology and pathophysiology with particular reference to gastrinoma.
Radioimmunoassay of gastrin
The ability to measure femtomol (10-I'M) amounts of gastrin by radioimmunoassay has led to intensive study of the release of the hormone. Since McGuigan (1968) first developed this assay for gastrin, numerous groups have followed and the assay is now widely available. The most useful gastrin antibodies are those that are directed against the C-terminus, measure all forms equally and do not cross react with other peptides that share the C-terminus such as cholecystokinin or caerulein. Using such antibodies, serum gastrin can be detected in unextracted samples at a dilution of 1:10 and usually measures amounts of 10-50 fmol ml-' in the fasting normal subject. Region specific antisera have been generated for the C and N terminus of gastrin 17, for unsulphated G 17, for G34 and the N terminus of G34. Utilizing these region specific antisera, the characterization of the various molecular forms of gastrin in plasma or tissues can be made without resort to gel filtration or affinity chromatography (Dockray, 1979) .
The gastrins
Gastrin exists in multiple molecular forms that not only differ in one or two amino acids in different species but also occur in different chain lengths within species. It is thought that a large precursor molecule, Pre-Pro-Gastrin, is synthesized in cells and undergoes post-translational enzymatic cleavage at specific arginine or lysine residue to yield first gastrin 34 and then gastrin 17 (Yanahaira, 1980) . In addition to there being molecules of different chain length, the molecules may have the single tyrosine sulphated or unsulphated. There is little doubt about six molecular forms of gastrin in mammals-G34 sulphated or unsulphated, G17 sulphated and unsulphated and G 14 sulphated and unsulphated. A form larger than G34 has been identified on gel chromatography and named 'Component I' but its structure has not yet been elucidated (Rehfeld, Stadil and Vikelsoe, 1974) . There has also been a peak eluting in the void volume of sephadex columns called 'big big gastrin' but this is probably an artefact. There is also controversy whether G4 exists in cells. The most abundant forms in blood and tissues are G34 and G17. G34 accounts for most of the fasting serum gastrin and for about half of that released by a stimulus. The predominant site of extractable gastrin is the antrum and the form is as G17. Gastrin can also be extracted from the duodenum where about half is G34. Sulphated and unsulphated forms are equally distributed.
Actions of gastrin and role in physiology
The full range of biological actions of gastrin reside in the C terminal tetrapeptide amide. G 17 and G 14 are equipotent in stimulating gastric acid secretion whereas G34 has about 1/6 the potency in the circulation. When infused exogenously, all three are equipotent on a molar basis. (Korman et al., 1972) . The role of these hormones in the physiology of gastrin release is not known and the effects may be pharmacological (Hansky, Soveny and Korman, 1971 ). Pathophysiology of gastrin release Ulcer disease. In duodenal ulcer, fasting serum gastrin levels are generally within the normal range but food stimulated gastrin levels are greater than in normal subjects . This, together with the finding that parietal cells in duodenal ulcer disease are more sensitive to gastrin (Lam et al., 1980) indicates some role for gastrin in the pathophysiology of duodenal ulcer. In gastric ulcer, basal levels of gastrin are elevated and there is a large release of food stimulated gastrin. This is probably consequent on the diminished acidity in the antrum due to concomitant gastritis . All forms of vagotomy in man lead to an increase in fasting serum gastrin and increased release after food stimulation. It is considered that this may be due to both removal of a vagal inhibitory mechanism and an increase in the gastrin cell mass (Hansen, Larsen and Svendsen, 1979) .
Hypergastrinaemia. The causes of an increase in fasting serum gastrin are shown in Table 4 . The group associated with hyperacidity, hypergastrinaemia and usually peptic ulceration form the most interesting and probably the commonest group. Gastrinoma will be considered separately and the hypergastrinaemia associated with massive small bowel resection has been reported only by Straus, Berson and Yalow (1974) but not confirmed by others. Retained excluded antrum and antral G cell hyperfunction are uncommon but definite entities. Retained excluded antrum was first described by Korman et al. in 1972, but only a few patients have been reported. Recently Basso et al. (1981) have assessed bombesin in differentiating between gastrin of antral origin and that from other sites. They found an increase in gastrin after bombesin in five patients with the retained antrum syndrome and postulated this as a good differentiating test. Antral G cell hyperfunction (hyperplasia) has been reported sporadically and consists of hypergastrinaemia, hyperacidity and peptic ulceration in the absence of definite evidence of a gastrinoma with a major distinguishing feature being a grossly exaggerated gastrin release after food. Some reports have indicated an increased number of G cells in these patients but the feature which distinguishes them from gastrinoma is that the serum gastrin returns to normal levels following antrectomy (Walsh, 1979) .
The differentiation of these three causes of hypergastrinaemia and hyperacidity is shown in Table 5 and is mainly based on the serum gastrin response to food and intravenous secretin injection as well as the fasting serum gastrin. Generally patients with gastrinoma have a very high fasting gastrin, a normal gastrin response to food and a paradoxical increase in gastrin to secretin. Antral G cell hyperfunction shows a moderately elevated fasting gastrin, an exaggerated response to food (over 400%o) and a fall in gastrin with secretin. Retained antrum is the same as antral G cell hyperfunction except that the response to food is poor. All three show a response to intravenous calcium infusion whilst the experience with bombesin is not large enough to permit an opinion on its value.
Chronic renalfailure
Studies on the metabolism of gastrin suggest that the kidneys are a major site of gastrin breakdown particularly for the G34 form. Hypergastrinaemia has been reported in patients with acute renal failure, after nephrectomy and in chronic renal failure. In a study on a large number of patients, it has been shown that the serum gastrin rises proportionally with the serum creatinine, the higher the creatinine, the higher the gastrin. The relationships of this increase in gastrin to acid secretion and peptic ulceration in this group ofpatients with chronic renal failure is not clear as most patients do not have ulcer problems (Hansky, 1979) .
Type A chronic atrophic gastritis Elevated serum gastrin is usually found in patients with type A chronic atrophic gastritis. This gastritis is characterized by a positive titre for parietal cell antibody, gastritis limited to the acid secreting part of the stomach with antral sparing and propensity towards development of pernicious anaemia. Gastrin levels are often the highest seen, increase with age and there is an exaggerated response to food suggest McCarthy, 1978) . Others have reported more failures with medical treatment with a greater incidence of total gastrectomy (Bonfils, Mignon and Gratton, 1979; Deveney et al., 1978) . A recent paper from the Mayo Clinic (Malagelada et al., 1983) (Richardson et al., 1979) .
Our own experience with medical therapy is based on 46 patients with gastrinoma. Twenty seven have been treated with cimetidine in doses ranging from 08-1 g daily; of these nine have had vagotomy and/or partial gastrectomy and are well controlled on cimetidine; 13 are controlled on larger doses of 1-5 g daily and five have failed cimetidine and are now controlled with ranitidine. Side effects from medication are minimal and all 27 patients are well. The 19 patients not treated with H2 receptor antagonists comprise four with tumour removal whose gastrins normalized, nine with total gastrectomy, two with MEA I who responded to parathyroidectomy and four patients who died from metastatic disease (Hansky, 1983) .
Based on our experience and the available literature, the recommended management option for gastrinoma is shown in Table 6 . If a tumour can be demonstrated on ultrasound, CT scanning, portal vein sampling or angiography then explore and attempt removal. If no tumour is found, cimetidine or ranitidine are commenced and the patient followed closely. Gastrin estimations are performed 3 monthly and if there is a sudden increase the patient is restudied sooner than 2 years. Medical therapy is dictated by side effects and relapse. I start the patient on cimetidine 1-l12 g daily and if not held will increase the dose up to 3 g daily then change to ranitidine at a dose of 300-600 mg daily. The alternative is to begin ranitidine from the outset. Failure on ranitidine previously meant total gastrectomy; with the availability of omeprazole, a substituted benzimidazole, this should be tried first or perhaps an anticholinergic can be added to the H2 receptor blocker. Patients with MEA I should have their other endocrinopathies treated and often the hyperacidity diminishes. If not, they are treated medically. The role of streptozotocin in metastatic disease is not clear but it does not seem to be as valuable as in other types of islet cell tumours.
This scheme is a guide to management and will certainly not apply to all patients, particularly those with fulminating ulcer disease which requires urgent gastrectomy. It is of some interest that in the 1950s and 60s these patients were not infrequently seen; more recently, they seem to have become much rarer, perhaps reflecting earlier diagnosis.
Summary
The past 20 years have seen gastrin attain true hormonal status. Its structure has been characterized, it has been synthesized, radioimmunoassays for its measurement in blood and tissues have been developed and its physiology and metabolism elucidated. Of much interest to clinicians has been the association between gastrin and tumours of the pancreas (gastrinomas) and atrophic gastritis. The advent of gastrin measurement has facilitated the diagnosis of gastrinoma and the availability of powerful acid suppressants has altered the therapy of gastrinoma.
